The primary aim is to investigate the effectiveness of Emotion Regulation Group Therapy (ERGT) for women who self-harm in ordinary psychiatric outpatient health care.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
97
Centre for Psychiatry Research Karolinska Institutet and Stockholm County Council
Stockholm, Sweden
Frequency of non-suicidal self-injury as measured by Deliberate Self-Harm Inventory (DSHI)
Change from Baseline in deliberate self-harm after 14 weeks and at 6- and 12 months after treatment has ended.
Time frame: Baseline (from inclusion to treatment start), (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks) and six and twelve months follow-up.
Borderline Symptom List Behavior supplement (BSL-supplement)
Change from Baseline in self-destructive behaviors after 14 weeks and at 6- and 12 months after treatment has ended.
Time frame: Baseline (from inclusion to treatment start), pre-treatment (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks), and six and twelve months follow-up.
Difficulties in Emotion Regulation Scale (DERS)
Change from Baseline in difficulties with emotion regulation after 14 weeks and at 6- and 12 months after treatment has ended.
Time frame: Baseline (from inclusion to treatment start), pre-treatment (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks) and six and twelve months follow-up.
Diary questionnaire (DQ)
Change from Baseline in positive and negative affect after 14 weeks and at 6- and 12 months after treatment has ended.
Time frame: Baseline (from inclusion to treatment start), pre-treatment (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks) and six and twelve months follow-up.
The Borderline Evaluation of Severity over Time (BEST).
Change from Baseline in Borderline severity symptoms after 14 weeks and at 6- and 12 months after treatment has ended.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up.
The Depression Anxiety Stress Scales (DASS)
Change from Baseline in depression and anxiety after 14 weeks and at 6- and 12 months after treatment has ended.
Time frame: Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up.
Inventory of Interpersonal Problems - Borderline Personality Disorder (IIP-BPD)
Change from Baseline in interpersonal problems after 14 weeks and at 6- and 12 months after treatment has ended.
Time frame: Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up.
Sheehan Disability Scale (SDS)
Change from Baseline in global functioning after 14 weeks and at 6- and 12 months after treatment has ended.
Time frame: Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up.
Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)
Change from Baseline in societal costs after 14 weeks and at 6- and 12 months after treatment has ended.
Time frame: Baseline, post-treatment (14 weeks) and six and twelve months follow-up.
Euroqol-5D (EQ-5D)
Change from Baseline in quality of life after 14 weeks and at 6- and 12 months after treatment has ended.
Time frame: Baseline, post-treatment (14 weeks) and six and twelve months follow-up.